WebDoctor Encyclopedia

Childhood Ovarian

Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT)

Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a very rare, aggressive ovarian cancer of girls and young women. It is caused by loss of the SMARCA4 gene, often raises blood calcium and needs intensive treatment.

Medically reviewed Last reviewed November 15, 2026

What is small cell carcinoma of the ovary, hypercalcaemic type?

Small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a very rare and aggressive ovarian cancer. Unlike most ovarian cancers, it mainly affects girls and young women, with an average age at diagnosis of about 24 years (Young, Oliva and Scully, 1994).

The name comes from two features. Under the microscope the cancer is made up of small, tightly packed cells. In about two-thirds of patients, the tumour also causes a high level of calcium in the blood (hypercalcaemia).

Almost all cases are caused by loss of a gene called SMARCA4. This gene normally helps to control how DNA is packaged and read (Witkowski et al., 2014).

Because SCCOHT is so rare, many specialists now regard it as a rhabdoid tumour of the ovary. It is related to the rhabdoid tumours that occur in the brain and kidneys of young children.

Treatment usually combines surgery, intensive chemotherapy and sometimes radiotherapy. Women and girls with SCCOHT, and their families, are offered genetic testing.

1. Key facts at a glance

Feature Details
Type of cancer Undifferentiated, rhabdoid-like ovarian cancer
How common Very rare; under 1% of ovarian cancers
Typical age Average about 24; range from early childhood to the mid-40s
Key gene SMARCA4 loss in over 90%
Inherited cases Germline SMARCA4 variants in a substantial minority
Raised calcium About two-thirds of patients
Usual sides Almost always one ovary
Main treatment Surgery and intensive chemotherapy, with radiotherapy or high-dose chemotherapy in some
Outlook Serious; best when the cancer is confined to one ovary

2. Causes and risk factors

In nearly every case of SCCOHT, both copies of the SMARCA4 gene are switched off in the tumour cells (Ramos et al., 2014; Jelinic et al., 2014).

SMARCA4 makes a protein called BRG1. BRG1 is part of the SWI/SNF complex, a group of proteins that open and close DNA so that genes can be turned on or off. Without it, cells lose control of growth and stay immature.

Factor Details
Germline SMARCA4 variant Inherited from a parent or arising new; found in a significant minority of patients
Family history Some families have several young women with SCCOHT
Age Mainly girls and women under 40

People with a germline SMARCA4 variant have rhabdoid tumour predisposition syndrome type 2. This raises the risk of SCCOHT and, less often, of other rhabdoid tumours.

Other risk factors linked with ovarian cancer, such as BRCA genes, endometriosis or older age, do not apply to SCCOHT.

Genetic counselling

Every patient with SCCOHT should be offered genetic counselling and germline SMARCA4 testing (Tischkowitz et al., 2020).

If a variant is found, sisters and other relatives can be tested. Women who carry the variant may be offered surveillance or risk-reducing removal of the ovaries once they have completed their family.

3. How does it look

Under the microscope

SCCOHT is made of sheets of small, round blue cells with little cytoplasm and many dividing cells. Some tumours contain fluid-filled spaces that look like small follicles.

About half include a large-cell variant, with bigger cells and more pink cytoplasm. Some cells may have a rhabdoid look, with an off-centre nucleus.

The most useful test is staining for BRG1 (SMARCA4) protein. Loss of BRG1 in the tumour cells strongly supports the diagnosis.

The tumour itself

Feature Typical finding
Size Usually large, often 10-15 cm or more
Sides Almost always one ovary
Cut surface Soft, fleshy, cream to tan, with areas of bleeding and dead tissue
Spread About half have spread beyond the ovary at diagnosis

On scans

Ultrasound, CT and MRI usually show a large, solid or mixed solid-cystic mass in the pelvis. Scans may also reveal fluid in the abdomen (ascites), deposits on the lining of the abdomen and enlarged lymph nodes.

Visible signs

Sign What it looks like
Swollen abdomen A visibly enlarged belly from the mass or fluid
Weight loss or thinner face and arms In advanced disease
Signs of dehydration Dry mouth and skin from high calcium causing frequent urination

4. Symptoms

Symptoms are often non-specific and can be mistaken for more common problems in young women, such as cysts or digestive complaints.

Common symptoms

  • Abdominal swelling or bloating
  • Pain in the abdomen or pelvis
  • A lump that can be felt in the lower abdomen
  • Feeling full quickly after eating
  • Nausea, vomiting or constipation
  • Changes in periods, in some patients
  • Tiredness and weight loss

Symptoms of high calcium

High calcium is often found on a blood test. It can, however, cause symptoms:

Symptom Description
Thirst and passing a lot of urine Calcium affects the kidneys
Nausea and loss of appetite Often with constipation
Tiredness and weakness Muscles and nerves work less well
Confusion or low mood With very high levels
Abdominal pain Sometimes from pancreatitis or kidney stones

The high calcium is caused by a hormone-like substance made by the tumour, called parathyroid hormone-related protein (PTHrP). Calcium usually returns to normal after the tumour is removed, and a rise in calcium can be an early sign of relapse.

When to seek medical advice

See a doctor promptly if you have persistent bloating, pelvic pain or a lump in the abdomen, even if you are young.

Seek urgent help for severe abdominal pain, vomiting, confusion or extreme thirst.

5. Diagnosis

Test Purpose
Pelvic ultrasound First test for a pelvic mass
CT or MRI scan Shows the size of the tumour and any spread
Blood calcium level Raised in about two-thirds
Tumour markers CA-125 may be raised; tests for germ cell tumours (AFP, hCG) are usually normal
Surgery and pathology Confirms the diagnosis, including BRG1 staining
SMARCA4 testing In the tumour and in blood for inherited variants

Conditions that can look similar

Condition How it differs
Adult granulosa cell tumour Older women; FOXL2 change; slower growth
Juvenile granulosa cell tumour Often makes hormones; BRG1 retained
Germ cell tumours (dysgerminoma) Raised tumour markers; different stains
Small cell carcinoma, pulmonary type Older women; neuroendocrine markers
Lymphoma Lymphoid markers on staining

Staging

SCCOHT is staged using the FIGO system for ovarian cancer, from stage I (confined to the ovary) to stage IV (spread outside the abdomen).

6. Treatment

Treatment should take place at a specialist gynaecological oncology centre, ideally one with experience of rare ovarian tumours and links with paediatric or sarcoma teams.

Surgery

Option Details
Complete staging surgery Removal of the ovaries, fallopian tubes and womb, with sampling of lymph nodes and the abdominal lining
Removing all visible tumour The aim in advanced disease
Fertility-sparing surgery Removal of one ovary only; rarely advised because of the high risk of recurrence

Experts usually recommend bilateral removal of the ovaries, even in young women. Fertility options, such as egg or embryo freezing, should be discussed before treatment where possible.

Chemotherapy

Most patients receive intensive combination chemotherapy after surgery (Callegaro-Filho et al., 2016; Tischkowitz et al., 2020).

Approach Details
Multi-drug regimens For example vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin and etoposide (VPCBAE)
Platinum and etoposide Used in some centres
High-dose chemotherapy with stem cell rescue Considered after initial treatment in some patients to consolidate response

Radiotherapy

Pelvic or whole-abdomen radiotherapy may be given after chemotherapy in some patients. Its role is still being studied.

Newer treatments

Treatment Status
EZH2 inhibitors (tazemetostat) Studied in SMARCA4-deficient tumours
Immune checkpoint inhibitors Responses reported in some patients
CDK4/6 inhibitors and other targeted drugs Under research
Clinical trials Recommended where available

Why intensive treatment is used

SCCOHT can grow and spread within weeks. For this reason, doctors usually recommend treatment that is more intensive than for common ovarian cancers, even when the cancer appears to be confined to one ovary.

Treatment is demanding, and it is usually given over several months. The care team will discuss its benefits and side effects openly, including the effects on hormones, fertility and daily life.

Treating high calcium

High calcium is treated with fluids through a drip, medicines such as bisphosphonates and, most importantly, treating the tumour itself.

7. Outlook (prognosis)

SCCOHT has a serious outlook. Many tumours have spread by the time they are found, and relapse is common, often within the first two years.

Factor Effect
Stage IA (one ovary, intact capsule) Best outlook; a proportion of patients are cured
Advanced stage Long-term survival is uncommon
Complete removal of tumour Better outlook
Intensive multimodal treatment Associated with better survival in case series
Normal calcium before surgery and small tumour size Linked with better outcomes in some studies

Because the disease is rare, results come from small studies and registries. International collaboration, including the International SCCOHT Consortium and patient registries, is helping to define the best treatment. Patients are encouraged to share their information with these registries, as each case helps to improve care for future patients.

8. Follow-up and living with SCCOHT

After treatment, regular follow-up includes examination, blood tests (including calcium) and scans. Visits are often every 3 months for the first two years and then less often.

Issue Support available
Early menopause Hormone replacement therapy is usually possible and helps protect bones and heart
Fertility loss Counselling and fertility services
Emotional impact Psychologists, specialist nurses and support groups for young adults with cancer
Family members Genetic counselling and testing

If the cancer comes back

A relapse is most often found within two years of treatment, in the abdomen or pelvis. A rising calcium level or new symptoms such as bloating and pain can be early signs.

Treatment options at relapse include further chemotherapy, surgery, radiotherapy and clinical trials of newer drugs. The aim may be to control the disease, relieve symptoms and maintain quality of life.

Fertility and hormones

Removing both ovaries causes an immediate menopause in girls and young women. Hormone replacement therapy is usually recommended until the natural age of menopause, unless there is a specific reason to avoid it.

Fertility specialists can discuss egg, embryo or ovarian tissue freezing before treatment. Pregnancy may later be possible using stored eggs or embryos, or donor eggs, if the womb has been kept.

9. Frequently asked questions

Question Answer
Is SCCOHT the same as other ovarian cancers? No. It affects younger women, has a different genetic cause and is treated differently
Why is my calcium high? The tumour makes a protein that raises calcium
Is it inherited? Sometimes. Germline SMARCA4 testing is recommended for every patient
Can I keep my fertility? Usually both ovaries are removed, but egg or embryo freezing may be possible beforehand
Should my sister be tested? If you carry a SMARCA4 variant, close relatives can be offered testing
Is it related to small cell lung cancer? No. Despite the similar name, SCCOHT is a different disease with a different cause
Where can I find support? Specialist nurses, teenage and young adult cancer services and the Small Cell Ovarian Cancer Foundation

10. Questions to ask your care team

  • What stage is my cancer?
  • Has BRG1 (SMARCA4) loss been confirmed?
  • Will I have genetic testing, and what does it mean for my family?
  • What treatment do you recommend, including high-dose chemotherapy?
  • What are my fertility options?
  • Are there clinical trials for SCCOHT?
  • How will my calcium levels be monitored during and after treatment?
  • Who will coordinate my care between the different specialist teams?

Resources

  1. Young, R.H., Oliva, E. and Scully, R.E. (1994) ‘Small cell carcinoma of the ovary, hypercalcemic type: a clinicopathological analysis of 150 cases’, American Journal of Surgical Pathology, 18(11), pp. 1102-1116.
  2. Witkowski, L. et al. (2014) ‘Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type’, Nature Genetics, 46(5), pp. 438-443.
  3. Ramos, P. et al. (2014) ‘Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4’, Nature Genetics, 46(5), pp. 427-429.
  4. Jelinic, P. et al. (2014) ‘Recurrent SMARCA4 mutations in small cell carcinoma of the ovary’, Nature Genetics, 46(5), pp. 424-426.
  5. Tischkowitz, M. et al. (2020) ‘Small-cell carcinoma of the ovary, hypercalcemic type – genetics, new treatment targets, and current management guidelines’, Clinical Cancer Research, 26(15), pp. 3908-3917.
  6. Callegaro-Filho, D. et al. (2016) ‘Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases’, Gynecologic Oncology, 140(1), pp. 53-57.
  7. Wade, I. et al. (2025) ‘Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)’, Genetics in Medicine, 27(1), p. 101287.
  8. Small Cell Ovarian Cancer Foundation (2026) Small Cell Ovarian Cancer Foundation. Available at: https://www.smallcellovarian.org/ (Accessed: October 2026).

Prepared by the editorial team, October 2026.